Heart disease was identified as a risk factor for mortality early in the COVID-19 pandemic. It was unknown if this risk would also apply to patients with congenital heart disease (CHD). To assess this risk, researchers conducted an international, multicenter retrospective study on 1044 patients with CHD who had been diagnosed with COVID-19. Infection was confirmed by … [Read more...] about COVID-19 in adults with congenital heart disease
Imaging
Top 10 Highlights of ACC 2021
The American College of Cardiology (ACC) 2021 scientific sessions took place virtually this year from 15-17 May. Here is our curated list of the top 10 highlights of these sessions. TALOS-AMI trial1: This trial followed 2697 patients who had experienced myocardial infarction (MI), undergone percutaneous coronary intervention (PCI), and completed 1 month of dual … [Read more...] about Top 10 Highlights of ACC 2021
COVID-19 and cardiac arrest, a lethal combination
Researchers compared outcomes of patients who had suffered in- and out-of-hospital cardiac arrest, before and after the onset of the COVID-19 pandemic (16 March 2020). Between 01 January and 20 July 2020, 3026 cardiac arrests were reported to the Swedish Registry for Cardiopulmonary Resuscitation. https://youtu.be/n8g-88glR-Q Of these 3026 cardiac arrests, 1946 occurred … [Read more...] about COVID-19 and cardiac arrest, a lethal combination
SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include elevated hepatic or muscular enzymes, neurological symptoms, and muscular symptoms collectively referred to as statin-associated muscle symptoms (SAMS).1 SAMS seems to occur less frequently in randomized control trials than in observational studies. These results suggest that … [Read more...] about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
Top 10 Highlights of AHA 2020 Congress
The American Heart Association (AHA) 2020 congress took place virtually this year, from November 13 to 17, 2020. Here is our curated list of the top scientific sessions from AHA 2020. SOLOIST-WHF trial1: Sotagliflozin superior to placebo in preventing deaths and hospitalizations in patients with type 2 diabetes and worsening heart failure. This multicenter, double-blind … [Read more...] about Top 10 Highlights of AHA 2020 Congress